Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…Abstract Number: 659 • 2015 ACR/ARHP Annual Meeting
Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Background/Purpose: The self-administered comorbidity questionnaire (SCQ) was developed to understand the impact of 13 common comorbidities on functioning and resource utilisation. In patients with ankylosing…Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…Abstract Number: 661 • 2015 ACR/ARHP Annual Meeting
ASDAS Can be Reliably Calculated When Only the Patient’s Overall Basdai Score Is Available, but Not the Score(S) of Its Individual Component(S)
Background/Purpose: ASDAS is a composite measure of disease activity for ankylosing spondylitis (AS). Its calculation includes three BASDAI questions, BASDAI Q2 (back pain), Q3 (peripheral…Abstract Number: 662 • 2015 ACR/ARHP Annual Meeting
Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population?
Background/Purpose: There is a need for screening questionnaires to identify patients with psoriasis who have undiagnosed psoriatic arthritis but the optimal method is unknown. We…Abstract Number: 663 • 2015 ACR/ARHP Annual Meeting
Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…Abstract Number: 664 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Assessment of the Quality of Life in a Cohort of Patients Affected By Enteropathic Spondyloarthritis: Definitive Results of a Monocentric Prospective Observational Study at One Year
Background/Purpose: Enteropathic spondyloarthritis (ES) are included in the group of the spondyloarthritis (SpA). Because articular involvement is the most frequent extra-intestinal manifestation in patients with…Abstract Number: 665 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Disease Activity for Psoriatic Arthritis Composite Index and Tentative Cut-Off Values in a Cohort of Patients with Psoriatic Arthritis
Background/Purpose: Disease Activity for Psoriatic Arthritis (DAPSA) is a composite index that assesses disease activity in patients with Psoriatic Arthritis (PsA) taking into account peripheral…Abstract Number: 666 • 2015 ACR/ARHP Annual Meeting
Disease Activity Indices and Body Mass Index: Cross-Sectional Analysis of a Large Psoriatic Arthritis Cohort
Background/Purpose: Well known comorbidities of Psoriatic arthritis (PsA) such as cardiovascular disease, metabolic syndrome and diabetes mellitus are closely related with body mass index (BMI).…Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…Abstract Number: 669 • 2015 ACR/ARHP Annual Meeting
Assessment of Spinal Mobility in Axial Spondyloarthritis: First Validation Steps of a New Electronic Quantification Tool
Background/Purpose: Spinal mobility is a major health issue of patients with axial spondyloarthritis (axSpA), especially in ankylosing spondylitis (AS) while non-radiographic axSpA (nr-axSpA) has been…Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…Abstract Number: 671 • 2015 ACR/ARHP Annual Meeting
Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Background/Purpose: Discordance between patient (pt) and physician (phy) assessment of disease activity (DA) in spondyloarthritis (SpA) is recognized, with phys tending to score DA less…
